Search results
Results from the Tech24 Deals Content Network
The results from the study saw Vascepa meeting its primary endpoints. This had providing a relative risk reduction of 25% when compared to those on a placebo. This is a major statistical ...
Barely a month ago, investors of Amarin (AMRN) were left dismayed following a lost patent trial against two generic drug makers seeking to sell their own versions of Amarin’s high triglycerides ...
Trading at under 35 times 2025 earnings estimates and with a price/earnings-to-growth (PEG) ratio of 1 times, the stock looks attractively valued for a growth stock that still has a number of good ...
amarincorp .com. Amarin Corporation is an Irish-American biopharmaceutical company founded in 1993 and headquartered in Dublin, Ireland and Bridgewater, New Jersey. [ 1] The company develops and markets medicines for the treatment of cardiovascular disease. It has developed the drug Vascepa (AMR-101), a prescription grade omega-3 fatty acid.
If you are looking for another successful biotech story in 2020, then look away now. Shares of Amarin (AMRN) have been under the cosh this year, as the company has battled its way through the ...
One week ago, Stifel analyst Derek Archila reiterated his "buy" rating on anti-cholesterol drugmaker Amarin (AMRN). He did this partly because he liked how Amarin's Q2 earnings report showed sales ...
Today, Amarin (AMRN) investors are scratching their heads as to why the stock tumbled following the announcement that the FDA has approved the label extension of the company’s fish oil drug ...
The European Commission (EC) has approved the marketing authorization application for Amarin Corporation Plc's (NASDAQ: AMRN) Vazkepa (icosapent ethyl) for cardiovascular risk reduction. The ...